Plymouth Meeting, Pennsylvania-based Inovio specializes in developing DNA vaccines and has created products to treat 15 indications. It is the only company to have a phase 2 vaccine for the coronavirus that caused Middle East respiratory syndrome, or MERS. The company was called on to help during the 2016 Zika outbreak and the Ebola outbreak in 2014.
Inovio Chief Executive Dr. J. Joseph Kim told the U.S. Coronavirus Task Force meeting at the White House on Monday that the company designed INO-4800 on Jan. 10 in three hours after the publication of the genetic sequence of the virus.
Market Data 
Markets 
AI
